CR10505A - Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden - Google Patents
Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprendenInfo
- Publication number
- CR10505A CR10505A CR10505A CR10505A CR10505A CR 10505 A CR10505 A CR 10505A CR 10505 A CR10505 A CR 10505A CR 10505 A CR10505 A CR 10505A CR 10505 A CR10505 A CR 10505A
- Authority
- CR
- Costa Rica
- Prior art keywords
- aminopirazolopiridinas
- preparations
- salts
- understand
- replaced
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06090109A EP1867648A1 (en) | 2006-06-13 | 2006-06-13 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. |
| EP07090020 | 2007-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10505A true CR10505A (es) | 2009-03-20 |
Family
ID=38445661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10505A CR10505A (es) | 2006-06-13 | 2008-12-12 | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7846928B2 (es) |
| EP (1) | EP2061790B1 (es) |
| JP (1) | JP5475442B2 (es) |
| KR (1) | KR20090018212A (es) |
| AR (1) | AR061346A1 (es) |
| AU (1) | AU2007260216A1 (es) |
| BR (1) | BRPI0711961A2 (es) |
| CA (1) | CA2654789C (es) |
| CL (1) | CL2007001711A1 (es) |
| CR (1) | CR10505A (es) |
| EA (1) | EA200802407A1 (es) |
| EC (1) | ECSP088963A (es) |
| ES (1) | ES2515117T3 (es) |
| GT (1) | GT200800285A (es) |
| IL (1) | IL195813A0 (es) |
| MX (1) | MX2008015955A (es) |
| NO (1) | NO20090171L (es) |
| PE (1) | PE20080205A1 (es) |
| TW (1) | TW200815438A (es) |
| UY (1) | UY30409A1 (es) |
| WO (1) | WO2007144204A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| US8173635B2 (en) | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| JP2011520809A (ja) * | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| US8653098B2 (en) | 2008-11-20 | 2014-02-18 | Genentech, Inc. | Pyrazolopyridine PI3K inhibitor compounds and methods of use |
| WO2011019780A1 (en) | 2009-08-11 | 2011-02-17 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| ES2460915T3 (es) | 2009-12-21 | 2014-05-16 | Novartis Ag | Piridinas fusionadas con heteroarilo disustituido |
| AU2013240139B2 (en) * | 2012-03-26 | 2017-02-23 | Arroyo Biosciences L.L.C. | Novel sphingosine 1-phosphate receptor antagonists |
| US20150164910A1 (en) * | 2012-06-15 | 2015-06-18 | The Regents Of The University Of Califonia | Antiviral compounds and methods of use |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| EP4567035A4 (en) * | 2022-08-05 | 2026-07-08 | Nextgen Bioscience Co Ltd | NEW COMPOUND USED AS A HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING IT |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670364B2 (en) * | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| KR100976076B1 (ko) | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제 |
| US20070293511A1 (en) * | 2003-12-22 | 2007-12-20 | Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation | Crf Receptor Antagonists and Methods |
| FR2876691B1 (fr) * | 2004-10-18 | 2006-12-29 | Sanofi Aventis Sa | Derives de pyridine, leur preparation, leur application en therapeutique |
| ATE554087T1 (de) * | 2004-10-29 | 2012-05-15 | Abbott Lab | Neue kinaseinhibitoren |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP1683796A1 (en) * | 2005-01-24 | 2006-07-26 | Schering Aktiengesellschaft | Pyrazolopyridines, their preparation and their medical use |
| PT1899333E (pt) * | 2005-06-27 | 2009-04-23 | Sanofi Aventis | Derivados pirazolopiridina como inibidores da cinase do receptor beta-adrenérgico 1 |
-
2007
- 2007-06-11 TW TW096121006A patent/TW200815438A/zh unknown
- 2007-06-12 UY UY30409A patent/UY30409A1/es not_active Application Discontinuation
- 2007-06-12 AU AU2007260216A patent/AU2007260216A1/en not_active Abandoned
- 2007-06-12 EP EP07764753.5A patent/EP2061790B1/en active Active
- 2007-06-12 ES ES07764753.5T patent/ES2515117T3/es active Active
- 2007-06-12 WO PCT/EP2007/005432 patent/WO2007144204A1/en not_active Ceased
- 2007-06-12 AR ARP070102552A patent/AR061346A1/es unknown
- 2007-06-12 KR KR1020097000562A patent/KR20090018212A/ko not_active Withdrawn
- 2007-06-12 CL CL2007001711A patent/CL2007001711A1/es unknown
- 2007-06-12 JP JP2009514716A patent/JP5475442B2/ja not_active Expired - Fee Related
- 2007-06-12 PE PE2007000741A patent/PE20080205A1/es not_active Application Discontinuation
- 2007-06-12 CA CA2654789A patent/CA2654789C/en not_active Expired - Fee Related
- 2007-06-12 BR BRPI0711961-5A patent/BRPI0711961A2/pt not_active IP Right Cessation
- 2007-06-12 EA EA200802407A patent/EA200802407A1/ru unknown
- 2007-06-12 US US11/761,672 patent/US7846928B2/en not_active Expired - Fee Related
- 2007-06-12 MX MX2008015955A patent/MX2008015955A/es not_active Application Discontinuation
-
2008
- 2008-12-09 IL IL195813A patent/IL195813A0/en unknown
- 2008-12-12 CR CR10505A patent/CR10505A/es not_active Application Discontinuation
- 2008-12-12 EC EC2008008963A patent/ECSP088963A/es unknown
- 2008-12-12 GT GT200800285A patent/GT200800285A/es unknown
-
2009
- 2009-01-12 NO NO20090171A patent/NO20090171L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007144204A1 (en) | 2007-12-21 |
| ES2515117T3 (es) | 2014-10-29 |
| PE20080205A1 (es) | 2008-06-01 |
| IL195813A0 (en) | 2009-09-22 |
| ECSP088963A (es) | 2009-01-30 |
| UY30409A1 (es) | 2008-01-31 |
| AR061346A1 (es) | 2008-08-20 |
| TW200815438A (en) | 2008-04-01 |
| EP2061790A1 (en) | 2009-05-27 |
| US7846928B2 (en) | 2010-12-07 |
| US20080058326A1 (en) | 2008-03-06 |
| JP5475442B2 (ja) | 2014-04-16 |
| EA200802407A1 (ru) | 2009-06-30 |
| CL2007001711A1 (es) | 2008-01-04 |
| AU2007260216A1 (en) | 2007-12-21 |
| BRPI0711961A2 (pt) | 2012-01-17 |
| EP2061790B1 (en) | 2014-08-13 |
| MX2008015955A (es) | 2009-01-09 |
| CA2654789A1 (en) | 2007-12-21 |
| CA2654789C (en) | 2014-08-05 |
| NO20090171L (no) | 2009-03-12 |
| GT200800285A (es) | 2009-03-09 |
| JP2009539914A (ja) | 2009-11-19 |
| KR20090018212A (ko) | 2009-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2018005I1 (lt) | Farmacinė kompozicija | |
| BRPI0807907A2 (pt) | co-cristais e composições farmacêuticas compreendendo os mesmos. | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| UA14280S (uk) | Футляр для косметичного виробу | |
| NO20075628L (no) | Farmasøytiske formuleringer | |
| DK2068886T3 (da) | Lipidholdige præparater | |
| DK3421471T3 (da) | Purin- og deazapurinderivater som farmaceutiske forbindelser | |
| EP2124556A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ITBO20050123A1 (it) | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina | |
| DK3984528T3 (da) | Farmaceutiske sammensætninger, som omfatter nilotinib | |
| DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
| DK2277509T3 (da) | DPP IV inhibitorformuleringer | |
| EP2128940A4 (en) | QUANTUM CASCADE LASER | |
| EP2101745A4 (en) | ADMINISTRATION OF MEDICINES | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
| EP2191826A4 (en) | PHARMACEUTICAL COMPOSITION | |
| DK2034951T3 (da) | Rehydererbart farmaceutisk produkt | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| DK2966175T3 (da) | Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat | |
| UY30410A1 (es) | Aminopirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| DK2120884T3 (da) | Farmaceutisk sammensætning | |
| EP2099789A4 (en) | INHIBITORS OF HIV REPLICATION | |
| PT2209464E (pt) | Composição farmacêutica antimalárica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |